|Day Low/High||36.92 / 37.34|
|52 Wk Low/High||33.79 / 40.43|
VANCOUVER, Sept.18, 2018 /CNW/ - The following issues have been halted by IIROC: Company: Sunniva Inc.
VANCOUVER, Aug. 29, 2018 /PRNewswire/ - Sunniva Inc.
VANCOUVER, Aug. 24, 2018 /PRNewswire/ - Sunniva Inc.
LONDON, July 25, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced positive clinical results concerning its JOURNEY™ II Bi-Cruciate Stabilized (BCS) knees.
VANCOUVER, July 17, 2018 /PRNewswire/ - Cannabis Strategic Ventures, Inc. (" Cannabis Strategic")( OTC Pink: NUGS) and Sunniva Inc.
LONDON and NEW YORK, July 3, 2018 /PRNewswire/ -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB)...
VANCOUVER, June 29, 2018 /PRNewswire/ - Sunniva Inc. (" Sunniva" or the " Company") ( CSE: SNN) ( OTCQX: SNNVF), a North American provider of cannabis products and services, is pleased to announce the voting results from its Annual General and Special...
VANCOUVER, June 18, 2018 /PRNewswire/ - Sunniva Inc. (" Sunniva" or the " Company") ( CSE: SNN) ( OTCQX:SNNVF), a North American provider of cannabis products and services, is pleased to announce that its wholly-owned subsidiary, Sunniva Medical Inc.
The appointment of Mike Weinstein as senior vice president of strategy has sparked the question of what the med tech firm should do to unlock shareholder value.
Investors in Smith & Nephew plc saw new options begin trading this week, for the December 21st expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, today announces the publication of a randomised controlled trial (RCT) demonstrating that the addition of ALLEVYN LIFE, Smith & Nephew's...
Activist investors have helped smaller shareholders win higher valuations for their holdings.
Paul Singer's Elliott is said to have started building a stake in the maker of artificial hips and knees, sending shares higher.
Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, proudly supports results of an independent, randomised clinical trial 1 concluding that, in the patients studied, the use of the PICO Single Use...
The FTSE 100 lagged its counterparts on Thursday following a run of broker downgrades and after a stronger pound ate into FX gains for London's blue chips.
Investors should look at cheap, inflation-proof stocks, which could be very cheap.
When interest rates rise, these quality dividend growth stocks should weather the storm.
Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, highlights three scientific symposia at World Union of Wound Health Societies (WUWHS) on 25-29 September 2016 in Florence, Italy.
The medical device company taps Jason Hannon, an 11-year company veteran, as its new president and COO, succeeding Patrick Miles, who was appointed vice chairman.
Smith & Nephew (LSE:SN)(NYSE:SNN), the global medical technology business, announces the publication of a new research paper showing how a comprehensive ulcer prevention programme which included the use of...
The $1 billion transaction could inspire other medical device companies and private equity firms to bend over backwards for spinal device assets.
The hefty premium Zimmer Biomet is paying in the $1 billion deal for the spine company suggests the target's management followed a competitive process.
The medical device company is spending $350 million for the gynecology business of Smith & Nephew, and has agreed to invest in an Israeli spinal robotics company.
The embattled pharmaceutical company's move to bring in additional directors and file an overdue financial report did little to appease the markets.
Medical device company Stryker is paying $1.2 billion cash for defibrillator maker Physio-Control on the heels of spending $2.8 billion on disposable health care devices manufacturer Sage Products.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.